See more : DXC Technology Company (0I6U.L) Income Statement Analysis – Financial Results
Complete financial analysis of ANI Pharmaceuticals, Inc. (ANIP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ANI Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Angel Fibers Limited (ANGEL.BO) Income Statement Analysis – Financial Results
- Flowserve Corporation (0IQE.L) Income Statement Analysis – Financial Results
- enVVeno Medical Corporation (HJLI) Income Statement Analysis – Financial Results
- Vulcan Energy Resources Limited (VUL.AX) Income Statement Analysis – Financial Results
- MAFIA TRENDS LIMITED (MAFIA.BO) Income Statement Analysis – Financial Results
ANI Pharmaceuticals, Inc. (ANIP)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.anipharmaceuticals.com
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 486.82M | 316.39M | 216.14M | 208.48M | 206.55M | 201.58M | 176.84M | 128.62M | 76.32M | 55.97M | 30.08M | 2.30M | 435.16K | 2.47M | 1.26M | 3.78M | 493.05K | 14.44M | 258.35K | 77.89K | 65.49K | 2.83M | 1.75M | 2.00 | 1.00 | 123.06K |
| Cost of Revenue | 181.51M | 138.79M | 100.61M | 87.16M | 63.15M | 73.02M | 79.03M | 48.78M | 12.69M | 11.47M | 9.97M | 9.17M | 50.00K | 268.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -24.29K | 0.00 | 0.00 |
| Gross Profit | 305.30M | 177.60M | 115.53M | 121.32M | 143.39M | 128.55M | 97.81M | 79.84M | 63.63M | 44.50M | 20.11M | -6.87M | 385.16K | 2.21M | 1.26M | 3.78M | 493.05K | 14.44M | 258.35K | 77.89K | 65.49K | 2.83M | 1.75M | 24.29K | 1.00 | 123.06K |
| Gross Profit Ratio | 62.71% | 56.13% | 53.45% | 58.19% | 69.42% | 63.77% | 55.31% | 62.07% | 83.37% | 79.50% | 66.84% | -298.44% | 88.51% | 89.14% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 1,214,600.00% | 100.00% | 100.00% |
| Research & Development | 34.29M | 22.32M | 11.37M | 16.00M | 19.81M | 15.39M | 9.07M | 2.91M | 2.87M | 2.68M | 1.71M | 16.89M | 44.18M | 39.71M | 13.68M | 15.79M | 4.75M | 3.86M | 6.41M | 9.16M | 3.69M | 4.79M | 2.14M | 1.89M | 660.59K | 1.40M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.06M | 31.58M | 27.83M | 21.16M | 17.94M | 16.39M | 8.23M | 6.98M | 5.94M | 5.67M | 5.96M | 4.33M | 7.03M | 3.05M | 3.08M | 2.33M | 1.77M | 2.30M | 1.68M | 853.39K | 1.11M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 161.70M | 124.04M | 84.29M | 64.99M | 55.84M | 44.06M | 31.58M | 27.83M | 21.16M | 17.94M | 16.39M | 8.23M | 6.98M | 5.94M | 5.67M | 5.96M | 4.33M | 7.03M | 3.05M | 3.08M | 2.33M | 1.77M | 2.30M | 1.68M | 853.39K | 1.11M |
| Other Expenses | 62.35M | 56.97M | 48.03M | 55.90M | 51.32M | -550.00K | 55.00K | -74.00K | 41.00K | 160.00K | -305.00K | 353.95K | 148.24K | 167.99K | 20.33M | 43.14K | 89.82K | 117.78K | 100.94K | 101.94K | 92.93K | 92.10K | 92.56K | 122.79K | 90.97K | 269.70K |
| Operating Expenses | 258.33M | 203.33M | 143.70M | 136.89M | 126.97M | 93.19M | 68.58M | 53.08M | 30.93M | 24.49M | 19.21M | 25.47M | 51.31M | 45.81M | 39.68M | 21.79M | 9.17M | 11.00M | 9.56M | 12.34M | 6.11M | 6.64M | 4.53M | 3.69M | 1.60M | 2.78M |
| Cost & Expenses | 439.85M | 342.12M | 244.31M | 224.05M | 190.12M | 166.22M | 147.61M | 101.86M | 43.62M | 35.96M | 29.18M | 25.47M | 51.36M | 46.08M | 39.68M | 21.79M | 9.17M | 11.00M | 9.56M | 12.34M | 6.11M | 6.64M | 4.53M | 3.66M | 1.60M | 2.78M |
| Interest Income | 0.00 | 28.05M | 11.92M | 9.45M | 12.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.54K | 8.33K | 12.67K | 11.65K | 588.46K | 1.10M | 428.34K | 401.19K | 250.42K | 86.59K | 63.79K | 174.42K | 227.72K | 0.00 | 0.00 |
| Interest Expense | 26.94M | 28.05M | 11.92M | 9.45M | 12.97M | 14.76M | 12.04M | 11.33M | 11.01M | 787.00K | 467.00K | 348.02K | 681.57K | 688.08K | 147.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 59.79M | 56.97M | 47.25M | 44.64M | 44.61M | 33.74M | 27.93M | 22.34M | 6.90M | 3.88M | 1.11M | 258.95K | 148.24K | 167.99K | 137.28K | 43.14K | 89.82K | 117.78K | 100.94K | 101.94K | 92.93K | 92.10K | 110.56K | 122.79K | 90.97K | 139.77K |
| EBITDA | 106.60M | 48.07M | -1.68M | 29.07M | 60.74M | 69.10M | 57.16M | 56.31M | 39.64M | 24.04M | 7.51M | -27.23M | -50.78M | -45.34M | -47.24M | -17.38M | -7.49M | 3.56M | -9.55M | -11.91M | -5.95M | -3.72M | -2.68M | -3.31M | -1.51M | -2.52M |
| EBITDA Ratio | 21.90% | 10.09% | 6.82% | 13.71% | 29.44% | 34.01% | 32.35% | 38.12% | 51.94% | 42.96% | 5.66% | -995.51% | -11,667.01% | -1,678.41% | -2,330.70% | -475.31% | -1,742.13% | 32.10% | -3,271.24% | -15,618.58% | -9,089.41% | -131.22% | -153.10% | -177,106,050.00% | -151,397,600.00% | -2,047.48% |
| Operating Income | 46.97M | -25.06M | -32.51M | -16.06M | 16.35M | 35.36M | 28.33M | 20.08M | 32.70M | 20.01M | 898.00K | -23.17M | -50.93M | -43.61M | -38.43M | -18.01M | -8.68M | 3.44M | -9.30M | -12.27M | -6.05M | -3.81M | -2.79M | -3.66M | -1.60M | -2.66M |
| Operating Income Ratio | 9.65% | -7.92% | -15.04% | -7.71% | 7.92% | 17.54% | 16.02% | 15.61% | 42.84% | 35.74% | 2.99% | -1,007.14% | -11,703.01% | -1,762.50% | -3,054.36% | -476.45% | -1,760.34% | 23.82% | -3,600.61% | -15,749.47% | -9,231.29% | -134.47% | -159.43% | -183,245,550.00% | -160,494,100.00% | -2,161.05% |
| Total Other Income/Expenses | -27.10M | -27.38M | -16.27M | -9.95M | -13.19M | -15.31M | -11.98M | -11.40M | -10.97M | -627.00K | -772.00K | -5.60M | -681.67K | -2.59M | -9.10M | -17.41B | -7.58B | -1.08M | -348.81K | 250.42K | 86.59K | 0.00 | 174.42K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 19.87M | -62.67M | -56.06M | -25.96M | 3.16M | 20.05M | 16.35M | 8.68M | 21.73M | 19.38M | 126.00K | -27.84M | -51.61B | -46.20B | -47.53B | -17.43B | -7.58B | 2.79B | -9.65B | -12.02M | -5.96M | -3.81M | -2.61M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 4.08% | -19.81% | -25.94% | -12.45% | 1.53% | 9.95% | 9.24% | 6.75% | 28.48% | 34.62% | 0.42% | -1,210.03% | -11,859,661.73% | -1,867,089.37% | -3,777,879.80% | -460,882.47% | -1,538,256.46% | 19,331.99% | -3,735,629.43% | -15,427.94% | -9,099.08% | -134.47% | -149.44% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.09M | -14.77M | -13.46M | -3.41M | -2.94M | 4.56M | 17.43M | 4.74M | 6.36M | -9.37M | 20.00K | -121.79K | 681.67K | 2.59M | 9.10M | -17.41B | -7.58B | 648.49K | 348.81K | 0.00 | 0.00 | 0.00 | 0.00 | -227.72K | -198.68K | 0.00 |
| Net Income | 18.78M | -47.90M | -42.60M | -22.55M | 6.09M | 15.49M | -1.08M | 3.93M | 15.38M | 28.75M | 301.00K | -27.72M | -51.61M | -46.20M | -47.53M | -17.43M | -7.58M | 2.79M | -9.65M | -12.02M | -5.96M | -3.81M | -2.61M | -3.44M | -1.41M | -2.66M |
| Net Income Ratio | 3.86% | -15.14% | -19.71% | -10.82% | 2.95% | 7.69% | -0.61% | 3.06% | 20.14% | 51.36% | 1.00% | -1,204.73% | -11,859.66% | -1,867.09% | -3,777.88% | -460.88% | -1,538.26% | 19.33% | -3,735.63% | -15,427.94% | -9,099.08% | -134.47% | -149.44% | -171,859,750.00% | -140,625,900.00% | -2,161.05% |
| EPS | 0.95 | -2.95 | -3.38 | -1.88 | 0.51 | 1.33 | -0.09 | 0.34 | 1.34 | 2.61 | -0.92 | -7.64 | -18.88 | -25.23 | -50.39 | -22.97 | -10.71 | 4.68 | -17.92 | -25.23 | -19.44 | -18.28 | -14.50 | -21.51 | -10.24 | -27.47 |
| EPS Diluted | 0.94 | -2.95 | -3.38 | -1.88 | 0.50 | 1.32 | -0.09 | 0.34 | 1.32 | 2.59 | -0.92 | -7.64 | -18.88 | -25.23 | -50.39 | -22.97 | -10.71 | 4.68 | -17.92 | -25.23 | -19.44 | -18.28 | -14.50 | -21.51 | -10.24 | -27.47 |
| Weighted Avg Shares Out | 18.00M | 16.26M | 12.60M | 11.96M | 11.84M | 11.68M | 11.55M | 11.45M | 11.37M | 10.94M | 5.07M | 3.63M | 2.73M | 1.83M | 943.11K | 758.54K | 707.93K | 588.64K | 538.67K | 476.26K | 306.63K | 208.42K | 180.15K | 159.82K | 137.29K | 96.83K |
| Weighted Avg Shares Out (Dil) | 18.19M | 16.26M | 12.60M | 11.96M | 12.04M | 11.77M | 11.55M | 11.57M | 11.56M | 11.05M | 5.07M | 3.63M | 2.73M | 1.83M | 943.11K | 758.54K | 707.93K | 596.78K | 538.67K | 476.26K | 306.63K | 208.42K | 180.15K | 159.82K | 137.29K | 96.83K |
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference
PRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the...
Does ANI (ANIP) Have the Potential to Rally 31.31% as Wall Street Analysts Expect?
The consensus price target hints at a 31.3% upside potential for ANI (ANIP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside...
ANI (ANIP) Upgraded to Buy: What Does It Mean for the Stock?
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q3 2024 Earnings Conference Call November 8, 2024 8:00 AM ET Company Participants Lisa Wilson - IR Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO...
Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.27 per share a year ago.
ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance
BAUDETTE, Minn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the three months ended September 30, 2024.
ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at at two upcoming investor...
Source: https://incomestatements.info
Category: Stock Reports